{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T05:46:25Z","timestamp":1751867185765},"reference-count":13,"publisher":"American Society for Microbiology","issue":"10","license":[{"start":{"date-parts":[[2017,9,25]],"date-time":"2017-09-25T00:00:00Z","timestamp":1506297600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"name":"Ross Southern Laboratories"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["J Clin Microbiol"],"published-print":{"date-parts":[[2017,10]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            The most reliable test method for the serological confirmation of Lyme disease (LD) is a 2-tier method recommended by the CDC in 1995. The first-tier test is a low-specificity enzyme-linked immunosorbent assay (ELISA), and the second-tier tests are higher-specificity IgG and IgM Western blots. This study describes the selection of two\n            <jats:named-content content-type=\"genus-species\">Borrelia burgdorferi<\/jats:named-content>\n            recombinant proteins and evaluation of their performance in a simple 1-tier test for the serological confirmation of LD. These two proteins were generated from (i) the full-length\n            <jats:italic>dbpA<\/jats:italic>\n            gene combined with the invariable region 6 of the\n            <jats:italic>vlsE<\/jats:italic>\n            gene (DbpA\/C6) and (b) the full-length\n            <jats:italic>ospC<\/jats:italic>\n            gene (OspC). The expressed DbpA\/C6 and OspC proteins were useful in detecting anti-\n            <jats:named-content content-type=\"genus-species\">Borrelia<\/jats:named-content>\n            IgG and IgM antibodies, respectively. A blind study was conducted on a well-characterized panel of 279 human sera from the CDC, comparing ELISAs using these two recombinant antigens with the 2-tier test method. The two methods (DbpA\/C6-OspC versus 2-tier test) were equivalent in identifying sera from negative-control subjects (99% and 100% specificity, respectively) and in detecting stage II and III LD patient sera (100% and 100% sensitivity). However, the DbpA\/C6-OspC ELISA was markedly better (80% versus 63%) than the 2-tier test method in detecting anti-\n            <jats:named-content content-type=\"genus-species\">Borrelia<\/jats:named-content>\n            antibodies in stage I LD patients. The findings suggest that these antigens could be used in a simple 1-tier ELISA that is faster to perform, easier to interpret, and less expensive than the 2-tier test method and which is better at detecting\n            <jats:named-content content-type=\"genus-species\">Borrelia<\/jats:named-content>\n            -specific antibodies in sera from patients with stage I LD.\n          <\/jats:p>","DOI":"10.1128\/jcm.01004-17","type":"journal-article","created":{"date-parts":[[2017,8,3]],"date-time":"2017-08-03T00:30:24Z","timestamp":1501720224000},"page":"3046-3056","update-policy":"http:\/\/dx.doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":11,"title":["Improved Serodiagnostic Performance for Lyme Disease by Use of Two Recombinant Proteins in Enzyme-Linked Immunosorbent Assay Compared to Standardized Two-Tier Testing"],"prefix":"10.1128","volume":"55","author":[{"given":"Gary L.","family":"Bradshaw","sequence":"first","affiliation":[{"name":"Ross Southern Laboratories, Spanish Fork, Utah, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. Kelley","family":"Thueson","sequence":"additional","affiliation":[{"name":"Ross Southern Laboratories, Spanish Fork, Utah, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Todd J.","family":"Uriona","sequence":"additional","affiliation":[{"name":"Ross Southern Laboratories, Spanish Fork, Utah, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00114"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0168613"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1542\/pir.35-12-500"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2011.03749.x"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.03394-15"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpath.2011.02.018"},{"key":"e_1_3_3_8_2","first-page":"590","article-title":"Recommendations for test performance and interpretation from the second national conference on serologic diagnosis of Lyme disease","volume":"44","author":"CDC","year":"1995","unstructured":"CDC. 1995. Recommendations for test performance and interpretation from the second national conference on serologic diagnosis of Lyme disease. Mord Mortal Wkly Rep44:590\u2013591.","journal-title":"Mord Mortal Wkly Rep"},{"key":"e_1_3_3_9_2","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1079\/9781845938048.0073","volume-title":"Lyme disease: an evidence-based approach","author":"Johnson BJB","year":"2011","unstructured":"Johnson BJB . 2011. Laboratory diagnostic testing for Borrelia burgdorferi infection, p 73\u201388. InHalperinJJ (ed), Lyme disease: an evidence-based approach. CAB International, Wallingford, UK."},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01409-14"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/iai.61.12.5097-5105.1993"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.66.5.2143-2153.1998"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00075-07"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/0003-2697(76)90527-3"}],"container-title":["Journal of Clinical Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/JCM.01004-17","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/JCM.01004-17","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,5]],"date-time":"2022-03-05T09:55:38Z","timestamp":1646474138000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/JCM.01004-17"}},"subtitle":[],"editor":[{"given":"Yi-Wei","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":13,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["10.1128\/JCM.01004-17"],"URL":"https:\/\/doi.org\/10.1128\/jcm.01004-17","relation":{},"ISSN":["0095-1137","1098-660X"],"issn-type":[{"value":"0095-1137","type":"print"},{"value":"1098-660X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"2017-06-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-07-28","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-09-25","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}